M30-L102 A Phase 3, Randomized, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System (20 mcg/day) and Mirena® for Long-Term, Reversible Contraception up to Five Years

Sponsor

Medicines360

Principal Investigator

Dr. Gretchen Stuart, Obstetrics and Gynecology

Project Run Dates

4/17/2012 to 4/16/2018

Total Award Amount

$92,279.30

 

Summary

The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who request long-term, reversible contraception.

 

Associated Publications and other materials

Study Record Detail via Clinical Trials.gov

 

Associated Award Numbers: A12-1105-002, A12-1105-003, A12-1105-004, A12-1105-005, A12-1105-006, A12-1105-007, A12-1105-008, A12-1105-009, A12-1105-010, A12-1105-011, A12-1105-012, A12-1105-013, A12-1105-014